The money and the moves.

IPO 30 Dec 2025, largest 2025 HK biotech IPO; Temasek cornerstone.

Last move: 30 Dec

On 10 June 2025 the company announced FDA clearance of its IND for NVC-001 in LMNA-related dilated cardiomyopathy, clearing the way for first-in-human clinical work. This followed the close of a US$45m Series B on 6 May 2025 raised to fund that clinical development, per the company's own newsroom (https://www.nuevocor.com/news).

Raised a A$65m Series A led by Airtree Ventures, announced 17 June 2026, with Plural, Left Lane Capital, b2venture and cricketer Pat Cummins participating. It came less than twelve months after a US$10m (A$15m) seed led by Left Lane Capital reported 24 July 2025, when the company cited a waitlist in the tens of thousands and planned international expansion (SmartCompany, 17 June 2026; Longevity.Technology, 24 July 2025).

Hims & Hers Health (NYSE: HIMS) completed its acquisition of Eucalyptus on 2 June 2026, for aggregate consideration of up to US$1.15bn subject to adjustments, per the acquirer's press release filed as an 8-K exhibit with the SEC. The deal was announced in February 2026; founder Tim Doyle moved into an international operations role at the acquirer.

Board and financial reset in early 2026: Tong Kooi Ong was appointed Independent Non-Executive Chairman effective 1 February 2026, succeeding Ng Ser Miang, in a move linked to the group's capital-intensive Johor Bay development in the Johor-Singapore Special Economic Zone. H1 2026 revenue rose to S$215.9m from S$201.9m a year earlier, with the net loss narrowing to S$10.2m, following an FY2025 loss driven by interest expense on the FV Hospital (Vietnam) acquisition and weaker Malaysian performance. (Reported via Simply Wall St; not independently confirmed against the SGX filing.)